Cambridge, Massachusetts, United States The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline TScan Therapeutics, Cadent Therapeutics, Vor Biopharma The fund has specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Health Care, Pharmaceutical.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Novartis Institutes for Biomedical Research, startups are often financed by Slater Technology Fund, Clal Biotechnology Industries, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are Novartis Venture Fund, Longwood Founders Fund, GV.
Related Funds
| Fund Name | Location |
| 3GP Capital | - |
| AdFirst.vc | Cyprus, Limassol |
| Boda Chuang Tou | Beijing, Beijing, China |
| Candide Group | California, Oakland, United States |
| GE Foundation | Connecticut, Fairfield, United States |
| Greenwood Way Capital | - |
| OSG Corporation | Aichi Prefecture, Japan, Toyokawa |
| Robus Capital Management | England, London, United Kingdom |
| Vectis Healthcare & Life Sciences Fund II | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $80M | 24 Feb 2021 | Cambridge, Massachusetts, United States | |||
Cadent Therapeutics | $15M | 29 Apr 2020 | Cambridge, Massachusetts, United States | ||
Pliant Therapeutics | $100M | 03 Mar 2020 | South San Francisco, California, United States | ||
TScan Therapeutics | $35M | 10 Jan 2020 | Massachusetts, United States | ||
TScan Therapeutics | 24 Jul 2019 | Massachusetts, United States | |||
Vor Biopharma | $42M | 14 Feb 2019 | Cambridge, Massachusetts, United States | ||
Cadent Therapeutics | $40M | 15 Nov 2018 | Cambridge, Massachusetts, United States | ||
Surface Oncology | $35M | 08 Jan 2015 | Cambridge, Massachusetts, United States |
– Orna Therapeutics, a biotechnology company dedicated to RNA therapeutics (oRNAs), announced the completion of its $80m Series A financing.
– The financing was co-led by MPM Capital, Taiho Ventures, and F2 Ventures, with participation from leading strategic investors: Kite, a Gilead Company, Bristol Myers Squibb, Astellas Venture Management, Novartis Institutes for Biomedical Research, and the PAGS Group.
– Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way disease is treated.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $80M | 24 Feb 2021 | Cambridge, Massachusetts, United States | |||
Cadent Therapeutics | $15M | 29 Apr 2020 | Cambridge, Massachusetts, United States | ||
Pliant Therapeutics | $100M | 03 Mar 2020 | South San Francisco, California, United States | ||
TScan Therapeutics | $35M | 10 Jan 2020 | Massachusetts, United States | ||
TScan Therapeutics | 24 Jul 2019 | Massachusetts, United States | |||
Vor Biopharma | $42M | 14 Feb 2019 | Cambridge, Massachusetts, United States | ||
Cadent Therapeutics | $40M | 15 Nov 2018 | Cambridge, Massachusetts, United States | ||
Surface Oncology | $35M | 08 Jan 2015 | Cambridge, Massachusetts, United States |
